Australia's most trusted
source of pharma news
Saturday, 27 July 2024
Posted 13 May 2024 PM
Kidney Health Australia has hailed the government's decision to subsidise yet another treatment option to come out of CSL's $17.2 billion buyout of Vifor Pharma.
This month, CSL Seqirus' Korsuva was listed on the PBS for moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing haemodialysis, marking a year-and-a-half since the novel treatment was TGA approved.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.